Skip to main content
. 2022 Feb 16;8:19. doi: 10.1038/s41523-022-00384-3

Fig. 4. Kaplan–Meier survival plots for distant recurrence-free survival (DRFS) based on TP53 mutation.

Fig. 4

Rates of DRFS according to TP53 mutations in a all patients, in b subset with good pathological (PR+/low HG/low Ki-67) outcomes, and in c patients given endocrine treatment alone (p = 0.046, p < 0.001 and p = 0.043, respectively; log-rank tests).